Second, the positive development process of Northeast Pharmaceutical 1993 was formally established in June. Northeast Pharmaceutical Co., Ltd. is one of the first batch of joint-stock pilot enterprises in Shenyang. It was among the top 500 Chinese enterprises in 2004 and the top 500 Chinese enterprises in 2005.
In 2004, "Northeast Pharmaceutical" was rated as one of the 500 most valuable brands in China by Davos World Economic Forum and World Brand Lab. In 2005, it was rated as one of the top ten pharmaceutical brands in China by the World Brand Lab, and ranked 247th on the list of China 500 most valuable brands in 2006 with a value of 2610.30 billion yuan. From June 5, 2006 to1October 23, 2006, as the first pilot enterprise of share-trading reform in Shenyang, Northeast Pharmaceutical successfully carried out the share-trading reform.
In addition, the "Northeast" brand was identified by the Ministry of Commerce as an export brand to be cultivated and developed in 2005-2006. For 20 years in a row, the enterprise has been awarded many honors, such as "Contract-abiding and Credit-abiding Enterprise" at the national level, "High-tech Enterprise" in Liaoning Province, Special Contribution Award for Foreign Trade Export, and Excellent Tax Paying Enterprise.
The enterprise has total assets of 3.5 billion yuan, more than 7,000 employees, annual sales income of nearly 4 billion yuan, and annual foreign exchange earned by self-export of nearly 654.38+0.5 billion US dollars.
Three. Northeast Pharmaceutical General Factory Group Introduction Northeast Pharmaceutical General Factory was established in 1946. It is the core enterprise of Northeast Pharmaceutical Group Co., Ltd., one of the comprehensive pharmaceutical industrial enterprises in China. It is mainly engaged in chemical synthesis, biological fermentation and pharmaceutical products, and is an important production and export base of pharmaceutical products in China. The enterprise mainly produces raw materials, pharmaceutical intermediates and preparations such as vitamins, antibiotics, cardiovascular and cerebrovascular diseases, antiviral diseases and digestive system diseases. There are more than 20 categories and hundreds of specifications of Dongyao's preparation products, including tablets, pills, capsules, suppositories, powders, granules, oral liquids, powder injections and other dosage forms. The enterprise also has a deep processing production base of feed additives and veterinary drugs based on the main raw materials.
The total assets of the enterprise are 3.46 billion yuan, and there are more than 6,000 registered employees. In 2008, the total industrial output value was 2.936 billion yuan, and the sales income was 3.0/kloc-0.20 billion yuan. The enterprise covers an area of nearly 1 10,000 square meters, with 17 production branches, national enterprise technology development center, pharmaceutical industry research institute, design institute, environmental protection research institute, quality inspection center, calculation center and other departments, as well as postdoctoral workstations and import and export companies that directly negotiate with foreign businessmen, forming a relatively complete production, management, scientific research and service system.
As one of the important pharmaceutical manufacturers in China, Northeast Pharmaceutical General Factory has a strong production capacity, with an annual production capacity of more than 30,000 tons of raw materials. The enterprise has advanced technology and equipment, and the economic and technical indicators of leading products are at the advanced international and domestic levels. The main products are: vitamin C series products, fosfomycin series products, L-carnitine series products, cephalosporin series products, sulfadiazine, berberine, vitamin B 1, sucralfate, amantadine, rimantadine, anti-AIDS drugs and so on.
The vitamin C production line of Northeast Pharmaceutical Factory is the largest in the world. All-chemical synthesis of berberine has independent intellectual property rights; The sales of fosfomycin sodium, Naofukang, vitamin B 1, sulfadiazine and L-carnitine rank among the top three in the world. Cefotaxime sodium selected by An Jingxian, an academician of China Academy of Engineering, was successfully developed for the first time in China. On 1985, it was listed for the first time in China and won the national scientific and technological progress award and the title of national and provincial famous brand products.
Approved by the State Administration of Pharmaceutical Products, Dongyao became the first manufacturer of anti-AIDS drugs in China. Products such as Keduo (zidovudine), Shazhi (stavudine), Hart (dehydroinosine) and indinavir sulfate have been put into production and supplied one after another according to national requirements, which has ended the history of China's total dependence on imports of anti-AIDS drugs, aroused widespread concern at home and abroad, brought hope for the survival of AIDS patients, and achieved good social benefits in the treatment and prevention of AIDS in China.
All products of Northeast Pharmaceutical Factory have passed the national GMP certification. The product quality conforms to the latest standards such as the United States Pharmacopoeia and the British Pharmacopoeia. Sulfadiazine and Naofukang passed the European COS certification; Sucralfate, amantadine and rimantadine have passed FDA certification. At the same time, the company is preparing to build a preparation production line that meets CGMP standards and undertake OEM of foreign preparation varieties. As early as 1999, the enterprise obtained the qualification certification of ——ISO9000 family standard, the authoritative quality system formulated by the International Organization for Standardization.
The product market covers a wide sales network, which is not only sold to all parts of China, but also exported to more than 70 countries and regions around the world. The annual export earnings are 65.438+0.5 billion US dollars. The marketing network of pharmaceutical products is all over the country, with hundreds of offices, and thousands of salesmen are active in cities and villages. Dongyao products enjoy a high reputation among consumers for their high quality, safety and exact curative effect.
In recent years, in accordance with the spirit of deepening the reform of state-owned enterprises, Northeast Pharmaceutical General Factory has vigorously promoted mechanism innovation, management innovation and technological innovation, respected knowledge and talents, and dominated the overall situation with innovation. The economic scale ratio of enterprises 1997 has increased by more than three times, and the profit level has been continuously improved. The company's "Northeast" brand drug trademark was awarded as a well-known trademark in China. "Northeast" brand was identified by the Ministry of Commerce as an export brand to be cultivated and developed in 2005-2006. At the same time, the enterprise has also been rated as a national contract-abiding and credit-abiding enterprise, a "high-tech enterprise" in Liaoning Province, a special contribution award for foreign trade export, an excellent tax paying enterprise and many other honors.
As a pharmaceutical industrial enterprise, Northeast Pharmaceutical General Factory always regards sustainable development as the ultimate goal of enterprise development. Enterprises attach great importance to environmental protection management. In the process of enterprise development, Dongyao resolutely implements relevant national and local laws and regulations, seriously declares pollution and approves sewage charges, and strictly abides by the "three simultaneities" management system of environmental protection. The drainage of the whole plant has reached the standard of entering the municipal sewage plant. In 2004, the enterprise built a comprehensive sewage treatment center (30,000 tons of industrial wastewater per day, COD 100 tons), which is the first in the pharmaceutical industry in China and the largest in Shenyang. Through the adjustment of product structure, the proportion of preparation products is increasing. Through the development of series products, deep processing and finishing, the product chain has been greatly enriched and the added value of products has been improved. The economic strength and management quality of enterprises have been further improved. Based on its own advantages in production, scientific research and market, Northeast Pharmaceutical General Factory will strengthen exchanges and cooperation with all sectors of society and make greater contributions to the development of China's pharmaceutical industry and people's health.
Four. Dongbei Pharmaceutical General Factory East Pharmaceutical Products This enterprise mainly produces raw materials such as vitamins, antibiotics, cardiovascular and cerebrovascular diseases, digestive system, pharmaceutical intermediates and preparations 100, and also produces related products such as veterinary drugs, food and feed additives.
The main products are vitamin C series, fosfomycin series, cephalosporin series, Naofukang, sulfadiazine, berberine, vitamin B 1, sucralfate, amantadine, rimantadine, anti-AIDS series, L-carnitine series, propargyl alcohol series, Kanglino and so on. The product quality conforms to the latest standards such as the United States Pharmacopoeia and the British Pharmacopoeia. The product market covers a wide sales network, which is not only sold to all parts of China, but also exported to more than 50 countries and regions in the world, earning foreign exchange through export annually 1.
Three hundred million dollars. As one of the important pharmaceutical manufacturers in China, Northeast Pharmaceutical General Factory has a strong production capacity, with an annual production capacity of more than 20,000 tons of raw materials.
For example, Northeast Pharmaceutical General Factory has the largest single vitamin C production line in the world, with independent intellectual property rights, and completely synthesizes berberine and other products. Fosfomycin sodium, Naofukang, vitamin B 1, sulfadiazine, L-carnitine and other products have high market share and advanced technology. All products have passed the national GMP certification, and three products, sucralfate, amantadine and rimantadine, have passed the US FDA certification inspection.
Verb (abbreviation of verb) What is the highest share price in the history of Northeast Pharmaceutical? The listing time of Northeast Pharmaceutical was1May 23, 1996, and 45 million shares were issued at an issue price of 6.68 yuan, raising a total of 300.6 million yuan.
2065438+On July 8th, 2004,1084.5 10/0,000 shares were issued at the price of 7.8 1 yuan, and the total amount of funds raised by the issuance was1100,000,000. The issuance method is non-public. At present, the stock market value of Northeast Pharmaceutical ranks 12 15 in standard industry, 323rd in operating income, 129 in ICB industry and 25th in operating income.
The highest stock price of Northeast Pharmaceutical Company appeared in 2009165438+1October 23rd, 29th.12 yuan.